Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Back to dashboard
Company Information
About this company
Key people
Richard J. Hawkins
Independent Chairman of the Board
Marc H. Hedrick
President, Chief Executive Officer, Director
Andrew Sims
Chief Financial Officer
Eric J. Daniels
Chief Development Officer
Ronald A. Andrews
Independent Director
Howard Clowes
Independent Director
Kyle Guse
Independent Director
Annigje van Es-Johansson
Independent Director
Click to see more
Key facts
- Shares in issue6.89m
- EPICPSTV
- ISINUS72941H8060
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap-$100.00bn
- Employees28
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.